Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Breast 1

Conditions

Sarcoma, Ewing 1Osteosarcoma 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1Chondrosarcoma 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × TQ-B3525 × Clear all
NCT04690725 2020-12-31

TQBSP

Peking University People's Hospital

Phase 1/2 Unknown
29 enrolled
Sarcoma

Chondrosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT04355520 2020-04-21

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
42 enrolled
Breast

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡